Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucie Oberic

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|December 14, 2019
Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIVCaroline Besson, Nicolas Noel, Remi Lancar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or OlderLucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Cancers|September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 YearsMaxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Neuro-Oncology|May 19, 2019
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network studyKarim Labreche, Mailys Daniau, Amit Sud, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
BMC Public Health|March 3, 2021
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohortHervé Ghesquières, Cédric Rossi, Fanny Cherblanc, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|December 14, 2019
Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIVCaroline Besson, Nicolas Noel, Remi Lancar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or OlderLucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Cancers|September 28, 2021
Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 YearsMaxime Jullien, Benoit Tessoulin, Hervé Ghesquières, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Neuro-Oncology|May 19, 2019
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network studyKarim Labreche, Mailys Daniau, Amit Sud, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
BMC Public Health|March 3, 2021
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohortHervé Ghesquières, Cédric Rossi, Fanny Cherblanc, et al.
Pageof 7